AU2001293538A1 - Novel protein tyrosine phosphatase inhibitor - Google Patents

Novel protein tyrosine phosphatase inhibitor

Info

Publication number
AU2001293538A1
AU2001293538A1 AU2001293538A AU9353801A AU2001293538A1 AU 2001293538 A1 AU2001293538 A1 AU 2001293538A1 AU 2001293538 A AU2001293538 A AU 2001293538A AU 9353801 A AU9353801 A AU 9353801A AU 2001293538 A1 AU2001293538 A1 AU 2001293538A1
Authority
AU
Australia
Prior art keywords
protein tyrosine
tyrosine phosphatase
novel protein
phosphatase inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293538A
Inventor
Kah Leong Lim
Catherine J. Pallen
Yin Hwee Tan
Haishan Wang
Yue Wang
Su Ling Yeo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular and Cell Biology
Original Assignee
Institute of Molecular and Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Molecular and Cell Biology filed Critical Institute of Molecular and Cell Biology
Publication of AU2001293538A1 publication Critical patent/AU2001293538A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001293538A 2000-09-08 2001-09-07 Novel protein tyrosine phosphatase inhibitor Abandoned AU2001293538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0022079 2000-09-08
GBGB0022079.8A GB0022079D0 (en) 2000-09-08 2000-09-08 Novel protein tyrosine phosphatase inhibitor
PCT/CA2001/001285 WO2002020525A2 (en) 2000-09-08 2001-09-07 Protein tyrosine phosphatase inhibitor

Publications (1)

Publication Number Publication Date
AU2001293538A1 true AU2001293538A1 (en) 2002-03-22

Family

ID=9899107

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293538A Abandoned AU2001293538A1 (en) 2000-09-08 2001-09-07 Novel protein tyrosine phosphatase inhibitor

Country Status (5)

Country Link
US (1) US7199121B2 (en)
AU (1) AU2001293538A1 (en)
CA (1) CA2421718A1 (en)
GB (1) GB0022079D0 (en)
WO (1) WO2002020525A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1383792A2 (en) 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Sh2 domain binding inhibitors
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US6642381B2 (en) 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
CA2509821A1 (en) * 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-phenyl analogs of toxoflavine as kinase inhibitors
WO2004007499A1 (en) * 2002-07-15 2004-01-22 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
EP1583747A2 (en) * 2002-12-31 2005-10-12 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
US20040242583A1 (en) 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
DE10301788B4 (en) * 2003-01-20 2005-08-25 Aventis Pharma Deutschland Gmbh Pharmaceutical use of pyrimido [5,4-e] [1,2,4] triazine-5,7-diones
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
ATE492275T1 (en) * 2005-04-15 2011-01-15 Einstein Coll Med VITAMIN K FOR PREVENTING AND TREATING SKIN RASH AS A RESULT OF ANTI-EGFR THERAPY
WO2007089857A2 (en) 2006-01-30 2007-08-09 Transtech Pharma, Inc. Substituted imidazole derivatives and their use as ptpase inhibitors
CA2656613A1 (en) 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
CN113072526B (en) * 2021-03-30 2022-09-13 滨州医学院 Anthraquinone/coumarin dimer compound and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069708A (en) * 1989-07-14 1991-12-03 Basf Aktiengesellschaft Pyrimido(5,4-e)-as-triazine-5,7(6H,8H)-diones

Also Published As

Publication number Publication date
US7199121B2 (en) 2007-04-03
US20040138218A1 (en) 2004-07-15
WO2002020525A3 (en) 2002-05-02
WO2002020525A2 (en) 2002-03-14
GB0022079D0 (en) 2000-10-25
CA2421718A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2001271427A1 (en) Novel proteases
AU2001269836A1 (en) Proteases
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2001271683A1 (en) Novel secreted proteins
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU6882598A (en) Protein kinase inhibitor
AU2001293538A1 (en) Novel protein tyrosine phosphatase inhibitor
AU2001264304A1 (en) Illuminator
AU2002233994A1 (en) Secreted proteins
AU2001238458A1 (en) Improved assay for protein tyrosine phosphatases
AU2001270045A1 (en) Secreted proteins
AU2002214286A1 (en) Method of profiling protein
AU2001255320A1 (en) Secreted proteins
AU2002239753A1 (en) Proteases
AU2001269888A1 (en) Protein phosphatases
AU2001283012A1 (en) Protein phosphatases
AU2001247483A1 (en) Proteases
AU2591299A (en) Human protein kinase c inhibitor
AU2001292870A1 (en) Protein phosphatases
AU2001292594A1 (en) Proteases
AU2001244863A1 (en) Apoptin-associating protein